Selected articles
Articles for label Melichar Bohuslav are displayed.. Show all articles
Prognostic significance of primary cilia in relation to selected parameters of the tumor microenvironment of clear cell renal cell carcinoma
04/2020 MUDr. Aneta Rozsypalová; MUDr. Blanka Rosová; Mgr. Alžběta Filipová, Ph.D.; MUDr. Dimitar Hadži Nikolov, Ph.D.; Mgr. Renata Chloupková; MUDr. Igor Richter, Ph.D.; MUDr. Jan Prokš; prof. MUDr. Radoslav Matěj, Ph.D.; prof. MUDr. Roman Zachoval, Ph.D.; prof. MUDr. Bohuslav Melichar, Ph.D.; doc. MUDr. Tomáš Büchler, Ph.D.; doc. MUDr. Josef Dvořák, Ph.D.
The presence of primary cilia, programmed cell death protein-1 receptor (PD-1) expression and intraepithelial CD8+ TIL (tumor infiltrating lymphocytes) expression were retrospectively evaluated in tumor tissue blocks of the resected specimens of the kidney in 104 patients with clear cell renal cell carcinoma. Median overall survival (OS) was significantly longer in patients with lower frequency of primary cilia (<0.002) than in patients with higher frequency of primary cilia (>0.002) (p<0.001). Median OS was significantly longer in patients with lower (<25%) CD8+ TIL expression than in patients with higher (>25%) CD8+ TIL expression (p=0.006). Median OS was significantly longer in patients with lower (<25%) PD-1 expression than in patients with higher (>25%) PD-1 expression (p=0.006). The present study provides the first data on the potential association and combined prognostic significance of frequency of primary cilia, CD8+ TIL expression and PD-1 expression in patients with clear cell renal cell carcinoma.
ENTIRE ARTICLE
The presence of primary cilia, programmed cell death protein-1 receptor (PD-1) expression and intraepithelial CD8+ TIL (tumor infiltrating lymphocytes) expression were retrospectively evaluated in tumor tissue blocks of the resected specimens of the kidney in 104 patients with clear cell renal cell carcinoma. Median overall survival (OS) was significantly longer in patients with lower frequency of primary cilia (<0.002) than in patients with higher frequency of primary cilia (>0.002) (p<0.001). Median OS was significantly longer in patients with lower (<25%) CD8+ TIL expression than in patients with higher (>25%) CD8+ TIL expression (p=0.006). Median OS was significantly longer in patients with lower (<25%) PD-1 expression than in patients with higher (>25%) PD-1 expression (p=0.006). The present study provides the first data on the potential association and combined prognostic significance of frequency of primary cilia, CD8+ TIL expression and PD-1 expression in patients with clear cell renal cell carcinoma.
Introduction to immunotherapy
Supplementum 01/2019 Imunoterapie
MUDr. Martina Spisarová; prof. MUDr. Bohuslav Melichar, Ph.D.
Tumor diseases are one of the most common causes of death worldwide and affect all ages. Current advances in malignant therapy are both in the field of surgical treatment, which remains a key curative method of early stages of the disease, as well as in the field of radiotherapy, chemotherapy and, last but not least, targeted treatments that help us to overcome the limits of standard cancer therapies. Even primarily effective targeted therapy often encounters the development of secondary resistance after a certain period of time. The role of the immune system, or the tumor cells escaping from its surveillance, is unquestionable in the development of cancer. Influencing the individual steps of the immune response seemed to be a very promising method how to influence the course of cancer, and in the last few years, this assumption has been confirmed by an ever-expanding number of diagnoses where modern immunotherapy in patients prolongs survival. The key diagnosis has become a disease that, thanks to its chemoresistance and radioresistance, for decades prompted the discovery of other treatment options.
ENTIRE ARTICLE
MUDr. Martina Spisarová; prof. MUDr. Bohuslav Melichar, Ph.D.
Tumor diseases are one of the most common causes of death worldwide and affect all ages. Current advances in malignant therapy are both in the field of surgical treatment, which remains a key curative method of early stages of the disease, as well as in the field of radiotherapy, chemotherapy and, last but not least, targeted treatments that help us to overcome the limits of standard cancer therapies. Even primarily effective targeted therapy often encounters the development of secondary resistance after a certain period of time. The role of the immune system, or the tumor cells escaping from its surveillance, is unquestionable in the development of cancer. Influencing the individual steps of the immune response seemed to be a very promising method how to influence the course of cancer, and in the last few years, this assumption has been confirmed by an ever-expanding number of diagnoses where modern immunotherapy in patients prolongs survival. The key diagnosis has become a disease that, thanks to its chemoresistance and radioresistance, for decades prompted the discovery of other treatment options.